BRISTOL MYERS SQUIBB

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Established: 1989-01-01

Employees: 30K

Market Cap: $97.5B

Website: https://www.bms.com/

Clinical Trials

Study to Assess the Safety of Nivolumab in the Treatment of Metastatic Melanoma, Lung Cancer, Renal Cancer, Squamous Cell Carcinoma of the Head and Neck, and Chronic Hodgkin Lymphoma in Adults in Mexico

Withdrawn

Conditions: Multiple Indications Cancer

Interventions: Other: Non-Interventional

First Posted Date: 2017-05-22

Last Posted Date: 2022-05-27

Lead Sponsor: Bristol-Myers Squibb

Registration Number: NCT03161613

Locations: 🇲🇽
Local Institution, Mexico, Distrito Federal, Mexico

A Study to Observe the Treatment Patterns and Outcomes of Patients in Japan With Kidney Cancer That is Unable to be Removed by Surgery or That Has Spread

Completed

Conditions: Renal Cell Carcinoma

First Posted Date: 2017-05-19

Last Posted Date: 2017-10-03

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 297

Registration Number: NCT03161145

Locations: 🇯🇵
Local Institution, Tokyo, Japan

A Study of Cabiralzumab Given by Itself or With Nivolumab in Advanced Cancer or Cancer That Has Spread

Phase 1

Completed

Conditions: Advanced Malignancies

Interventions: Biological: Cabiralizumab
Biological: Nivolumab

First Posted Date: 2017-05-18

Last Posted Date: 2020-12-21

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 19

Registration Number: NCT03158272

Locations: 🇯🇵
Local Institution, Chuo-ku, Tokyo, Japan

Real-World Evidence and Treatment Patterns: Head and Neck Cancer

Completed

Conditions: Head & Neck Cancer

Interventions: Other: Non-Interventional

First Posted Date: 2017-05-17

Last Posted Date: 2024-01-05

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 43994

Registration Number: NCT03157674

Locations: 🇯🇵
Local Institution, Tokyo, Shibuya-ku, Japan

A Study to Evaluate Efficacy in Subjects With Esophageal Cancer Treated With Nivolumab and Ipilimumab or Nivolumab Combined With Fluorouracil Plus Cisplatin Versus Fluorouracil Plus Cisplatin

Phase 3

Completed

Conditions: Various Advanced Cancer

Interventions: Biological: Nivolumab
Drug: Cisplatin
Biological: Ipilimumab
Drug: Fluorouracil

First Posted Date: 2017-05-08

Last Posted Date: 2025-02-25

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 970

Registration Number: NCT03143153

Locations: 🇨🇴
Local Institution - 0224, Monteria, Colombia
🇨🇴
Local Institution - 0094, Pereira, Colombia
🇨🇿
Local Institution - 0083, Brno, Czechia

and more 187 locations

A Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BMS-986263 in Healthy Participants

Phase 1

Completed

Conditions: Fibrosis

Interventions: Other: Placebo
Drug: BMS-986263
Drug: Diphenhydramine
Drug: Famotidine

First Posted Date: 2017-05-05

Last Posted Date: 2018-01-12

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 33

Registration Number: NCT03142165

Locations: 🇺🇸
Wcct Global, Llc, Cypress, California, United States

A Study of Nivolumab Combined With Cabozantinib Compared to Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma

Phase 3

Active, not recruiting

Conditions: Renal Cell Carcinoma

Interventions: Biological: Nivolumab
Biological: Ipilimumab
Drug: Sunitinib
Drug: Cabozantinib

First Posted Date: 2017-05-04

Last Posted Date: 2025-06-06

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 701

Registration Number: NCT03141177

Locations: 🇯🇵
Local Institution - 0148, Akita-shi, Akita, Japan
🇯🇵
Local Institution - 0156, Hirosaki, Aomori, Japan
🇯🇵
Local Institution - 0157, Sapporo-shi, Hokkaido, Japan

and more 132 locations

A Study of Nivolumab Plus Brentuximab Vedotin Versus Brentuximab Vedotin Alone in Patients With Advanced Stage Classical Hodgkin Lymphoma, Who Are Relapsed/ Refractory or Who Are Not Eligible for Autologous Stem Cell Transplant,

Phase 3

Terminated

Conditions: Hodgkin's Disease

Interventions: Biological: Brentuximab vedotin
Biological: Nivolumab

First Posted Date: 2017-05-03

Last Posted Date: 2024-01-10

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 23

Registration Number: NCT03138499

Locations: 🇺🇸
UCLA Clinical and Translational Research Center (CTRC), Los Angeles, California, United States
🇺🇸
University of Pennsylvania, Philadelphia, Pennsylvania, United States
🇺🇸
Dana Farber/Harvard Cancer Center, Boston, Massachusetts, United States

and more 17 locations

A Study Comparing Nivolumab, Nivolumab in Combination With Ipilimumab and Placebo in Participants With Localized Kidney Cancer Who Underwent Surgery to Remove Part of a Kidney

Phase 3

Completed

Conditions: Carcinoma, Renal Cell

Interventions: Drug: nivolumab placebo
Biological: nivolumab
Drug: ipilimumab placebo
Biological: ipilimumab

First Posted Date: 2017-05-03

Last Posted Date: 2024-12-18

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 1641

Registration Number: NCT03138512

Locations: 🇺🇸
Local Institution - 0019, Birmingham, Alabama, United States
🇺🇸
Local Institution - 0056, Springdale, Arkansas, United States
🇺🇸
Local Institution - 0186, Los Angeles, California, United States

and more 195 locations

A Study to Evaluate the Safety and Efficacy of Nivolumab Monotherapy and Nivolumab in Combination With Ipilimumab in Pediatric Participants With High Grade Primary Central Nervous System (CNS) Malignancies

Phase 2

Completed

Conditions: Various Advanced Cancer

Interventions: Biological: Nivolumab
Biological: Ipilimumab

First Posted Date: 2017-04-27

Last Posted Date: 2022-08-09

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 166

Registration Number: NCT03130959

Locations: 🇺🇸
Local Institution - 0046, Gainesville, Florida, United States
🇺🇸
Local Institution - 0011, Chicago, Illinois, United States
🇺🇸
Local Institution - 0017, New York, New York, United States

and more 50 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy